Hannes Snellman advises Novax in its investment in super gazelle company ApoEx AB

Novax, part of the Axel Johnson Group, has acquired 46% of ApoEx AB, a distributor of pharmaceuticals and consumable goods to public as well as private healthcare providers in Sweden. Founded in 2009, ApoEx was 2014 declared a “super gazelle” company by Dagens Industri and today has around 110 employees, more than 4,500 customers and an annual turnover of approximately SEK 1.7 billion.

Hannes Snellman advised Novax in relation to the investment. The deal team consisted of Jan Jensen together with, among others, Patrik Erblad, Axel Resvik, Aina Renström and Sofie Ovesen. Peter Forsberg and Xandra Carlsson advised on competition law aspects, and Carl-Magnus Uggla provided tax advice.